Latest developments in Alzheimer's drug discovery

Accelerating the development of innovative treatments for Alzheimer’s disease and related dementias is the target for scientists brought together at the 14th International Conference on Alzheimer’s Drug Discovery, and the focus of a special thematic series in Alzheimer’s Research & Therapy.

Hosted by the Alzheimer’s Drug Discovery Foundation (ADDF), on 9 – 10 September 2013 in Jersey City, USA, academic and industry scientists will attend the annual conference to highlight scientific progress on drug discovery programs aimed at treating Alzheimer’s disease and related dementias, as well as forming partnerships with fellow researchers.

Early bird registration ends this Friday, 9th August  – don’t miss out!

ADDF is a public charity supporting the advancement of drugs to prevent, treat, and cure Alzheimer’s disease, related dementias, and cognitive aging.

Alzheimer’s Research & Therapy is proud to have the Executive Director of ADDF, Professor Howard Fillit, on its international Editorial Board. Fillit is also Series Editor for a special series in the journal, ‘Cognitive Enhancers for Aging and Alzheimer’s disease’, which presents new approaches to drug discovery and development for therapeutics to treat cognitive aging.

We welcome research manuscripts that present new cognitive-enhancing drug strategies, including approaches that use supplements or nutritional aids. The publication of these articles are co-ordinated with a series of commissioned reviews and opinions written by leaders in the field. Contributors so far include María Javier Ramírez (University of Navarra, Spain) who reviews evidence supporting the cognitive effects of 5-HT6 receptor compounds and Allan Levey (Emory University, USA) who discusses treatments that target norepinephrine in MCI and AD.

If you would like to enquire about the suitability of a study for consideration, please email Otherwise please submit online and indicate in your covering letter that you would like the article to be considered for the cognitive enhancers series.

Alzheimer’s Research & Therapy is an international, peer-reviewed journal with an Impact Factor of 4.39. For further information about the journal, please visit the website, or contact us for enquires about the special series. To access all subscription content, including peer-reviewed reviews, commentaries and viewpoints, register for a free online trial to the journal and sign up for article alerts.

View the latest posts on the On Medicine homepage